A 12-month, prospective, randomized, active-controlled, open-label study to evaluate the patient retention of fingolimod versus - Bronson Healthcare

Multiple Sclerosis

A 12-month, prospective, randomized, active-controlled, open-label study to evaluate the patient retention of fingolimod versus approved first-line disease modifying therapies in adults who are in early stages of treatment for relapsing remitting multiple sclerosis (PREFERMS).

Objective

The main goal of this study is to evaluate how well fingolimod works by seeing how long patients stay on treatment. The study will also compare reasons for discontinuation, adverse events, changes in thinking skills, medication satisfaction and change in brain volume measured by MRI.

ClinicalTrials.Gov Number
NCT01623596
Principal Investigator(s)
Kelly Ybema, MD
Sponsor(s)
Novartis Pharmaceuticals
Contact
Brianna Johnson, BS, CCRC at 269-341-8410
or johnsobr@bronsonhg.com
How to Participate
Patients who can participate in the study will be in early stages of the disease and have had no treatment or have only been treated with one class of medicines (Interferon beta preparation or glatiramer acetate) for no more than 5 years total exposure. Patients will be able to switch to different treatment for safety, efficacy, tolerability or convenience during the study.
The study will last 1 year and will involve 1000 patients at multiple centers in the United States. Patients will be randomly assigned either to fingolimod or to approved disease modifying therapy.
More information can be found here

Location

  • Bronson Neuroscience Center - Kalamazoo
    601 John St.
    Suite M-124
    Kalamazoo, MI 49007
    Main: 269-341-7500
    Alternate: 888-258-0875
    Fax: 269-341-7540